Eledon Pharmaceuticals Inc
Statements
Cash Flow
Eledon Pharmaceuticals Inc (ELDN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -23 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.2 | -7.3 | -3.1 | -5.8 | -3.4 | -2.6 | -2.3 | -3.3 | -2.9 | -3.4 | -4.0 | -4.9 | -2.9 | -2.0 | -2.2 | -3.0 | -0.6 | -9.4 | -5.2 | -7.4 | -7.1 | -9.2 | -8.2 | -6.2 | -4.6 | -9.5 | -9.9 | -8.2 | -12 | -9.1 | -8.7 | -7.8 | -12 | -19 | -16 | -18 | -14 | -14 | -23 | -23 | -74 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | – | – | – | 0.1 | – | – | – | |
| 0.1 | 0.3 | 0.1 | 0.1 | 0.2 | – | 0.2 | 0.4 | 0.2 | 0.7 | 0.2 | 0.6 | 0.2 | 0.2 | 0.4 | 0.2 | 0.9 | 1.7 | 1.8 | 2.0 | 2.0 | 2.1 | 2.2 | 2.3 | 2.2 | 1.5 | 1.4 | 1.7 | 1.7 | 1.7 | 1.7 | 3.1 | 1.8 | 6.6 | 2.9 | 2.7 | 2.4 | 2.5 | 2.2 | 3.2 | 10 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 2.1 | 5.3 | 0.2 | 0.9 | 1.3 | 1.3 | 1.4 | 1.4 | 1.5 | 2.2 | 2.3 | 2.2 | 1.6 | 1.4 | 1.6 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.9 | -3.9 | 0.3 | -1.5 | -0.6 | -1.2 | 0.4 | -0.6 | 0.3 | 0.5 | 0.6 | -1.5 | -0.3 | 0.0 | 0.7 | -0.7 | 4.7 | -4.8 | 2.0 | -1.6 | 1.3 | -1.9 | -0.6 | 0.6 | 3.6 | -1.3 | -0.6 | -0.4 | -3.2 | -0.7 | 0.3 | 3.2 | 6.8 | -1.5 | -1.8 | 3.5 | 2.8 | 4.7 | -4.4 | -3.6 | -0.5 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 16 | 12 | 4.3 | 19 | – | – | -4.2 | – | – | – | – | – | – | 11 | 11 | 11 | 11 | 11 | – | – | – | – | – | – | -30 | -30 | -30 | -30 | -25 | – | – | -20 | -13 | -47 | 3.9 | 15 | 12 | -20 | 6.0 | 23 | 21 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 2.9 | – | 0.4 | 7.1 | – | 0.8 | 7.5 | – | 0.1 | 0.0 | 0.1 | 9.6 | – | 0.0 | 5.2 | 95 | 95 | 9.2 | -0.5 | -0.5 | 0.0 | -0.5 | 0.0 | 0.0 | 33 | 33 | 33 | 33 | 0.0 | 0.0 | 0.0 | 48 | 5.3 | 80 | 0.1 | 0.0 | 0.0 | 54 | 0.0 | 0.1 | 54 | |
| 6.5 | 4.6 | 1.2 | -1.8 | -3.4 | -1.9 | 5.2 | -3.3 | -2.9 | -3.4 | -3.9 | 4.6 | -2.9 | -2.0 | 3.0 | -3.0 | 106 | -0.3 | -5.6 | -7.4 | -7.1 | -9.2 | -8.2 | -6.2 | -4.6 | -9.5 | -9.9 | -5.5 | -37 | 0.9 | 1.0 | 20 | -19 | 14 | -12 | -2.8 | -2.1 | 19 | -17 | 0.7 | 1.1 | |
| -9.2 | -7.3 | -3.1 | -5.8 | -3.4 | -2.6 | -2.3 | -3.3 | -2.9 | -3.4 | -4.0 | -4.9 | -2.9 | -2.0 | -2.2 | -3.0 | -0.6 | -9.4 | -5.2 | -7.4 | -7.1 | -9.2 | -8.2 | -6.2 | -4.6 | -9.5 | -9.9 | -8.2 | -12 | -9.1 | -8.7 | -7.8 | -12 | -19 | -16 | -18 | -14 | -14 | -23 | -23 | -74 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.